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A B S T R A C T
Rationale and objective: Hodgkin lymphoma (HL) is largely curable owing to improvements in treatment
since the 1960s; nevertheless, high mortality rates have been reported in Central and South America. We
describe the current burden of HL in the Central and South American region.
Methods: We obtained regional- and national-level incidence data from 48 population-based cancer
registries in 13 countries, and national-level mortality data from the WHO mortality database for
18 countries. We estimated world population age-standardized incidence rates (ASRs) and age-
standardized mortality rates (ASMRs) per 100,000 person-years for 2003–2007 and present distributions
by histological subtype.
Results: HL incidence rates varied 7-fold in males and 11-fold in females (male-to-female ratio 1:1–2.5:1).
The highest ASRs were seen Argentina, Brazil, Costa Rica (males), Cuba (males) and Uruguay (females),
whereas the lowest were in Bolivia and El Salvador. ASMRs varied by 4-fold in males and 6-fold in females
(male-to-female ratio 1:1–4.3:1), with ASMRs <0.7 for most countries, except Cuba (1.0). In most
countries, age-speciﬁc incidence rates of HL showed a bimodal pattern. Trends in HL in Argentina, Brazil,
Chile, and Costa Rica remained stable in 1997–2008. Of all HL cases, 48% were unspeciﬁed as to
histological subtype. Nodular sclerosis and mixed cellularity were the most frequent histologies.
Conclusion: The geographic variation in HL across the region may in part reﬂect differences in data quality
and coverage, and differences in the adoption of modern therapies and healthcare access. Our results
highlight the need for high-quality data and increased coverage in order to provide vital guidance for
future cancer control activities.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Despite Hodgkin lymphoma (HL) accounting for no more than
0.5% of the total cancer burden worldwide in 2012 [1], its unusual
biology and epidemiology and positive response to treatment has
drawn the attention of clinicians, pathologists and researchers [2].
HL is classiﬁed – on the basis of differences in histology,
morphology and immunophenotype of the tumor cells – into$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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1877-7821/ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd
creativecommons.org/licenses/by-nc-nd/3.0/igo/).two major types: classical HL (cHL) and nodular lymphocyte-
predominant HL (NLPHL), accounting for 95% and 5% of all HL cases,
respectively [3]. cHL is further subdivided into nodular sclerosis
(NS), mixed cellularity (MC), lymphocyte-rich, and lymphocyte-
depleted types [4]. Initial treatment is based on histological
characteristics, stage at diagnosis, and other prognostic factors [5].
HL is largely curable owing to improvements in treatment since the
1960s [6,7], with survival rates of 80.8% and 85.2% in Europe and in
the United States, respectively [7,8]. Although the etiology of HL is
complex and poorly understood, comparisons in age-speciﬁc
incidence rates of HL, speciﬁc incidence patterns by sex and
socioeconomic status for speciﬁc subtypes of HL have provided
critical clues in the etiology of this disease [2,9–13]. For instance,
age-speciﬁc incidence rates of HL are bimodal, with the ﬁrst peak
occurring at age 15–34 years and the second after age 60 years,
speciﬁcally in European, American, Hispanic and Australian
populations [14], whereas in developing countries the incidence
of HL is characteristically high in early childhood and among the
oldest age groups. Afﬂuent standards of living during early. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
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adult HL, suggesting a delayed exposure to a common infectious
agent, while the opposite is true for children living in less favorable
living conditions [12,13,15].
GLOBOCAN estimates indicated that nearly 66,000 HL incident
cases and more than 25,000 HL deaths occurred globally in 2012,
with the vast majority (56% and 75%, respectively) occurring in less
developed regions of the world. (Developed regions include all
regions of Europe, Northern America, Australia/New Zealand and
Japan. Less developed regions include: all regions of Africa, Asia
(excluding Japan), Latin America and the Caribbean, Melanesia,
Micronesia and Polynesia.) Approximately 8–9% of the global
burden of new HL cases and deaths were estimated to occur in the
Central and South American region [1,16]. Recent predictions
indicate an increase of 54% in the absolute number of HL cases in
Central and South America for the year 2030, owing to growth and
aging of the population [1,16].
Declines in HL mortality have been reported in Europe, the
United States and Japan over the last few decades, largely because
of the adoption of modern therapies [17,18]. Declines in HL
mortality have also been described in several Latin American
countries (including the Caribbean) in the past decade. In spite of
the reported declines, elevated mortality rates occurred in Costa
Rica, Cuba, Mexico and Venezuela, probably reﬂecting differences
in healthcare access and management of this disease [6,19,20].
Unfortunately, HL incidence data in the Central and South
American region are lacking given the small number of cancer
registries that have met the data quality standards to be included in
Cancer Incidence in Five Continents [21]. Statistics on incidence
and mortality from HL are essential to identify disparities in cancer
burden, to develop and evaluate cancer control policies and
programs, as well as to guide future areas of research [22]. In this
paper we describe the current burden of HL in the Central and
South American region and interpret the data patterns in light of
factors known to increase the risk of HL.
2. Methods
The present analysis includes Hodgkin lymphoma (C81), as
coded by the 10th edition of the International Classiﬁcation of
Diseases for Oncology (ICD-10). The data sources and methods are
described in detail elsewhere in this issue. In brief, we obtained
regional- and national-level incidence data from 48 population-
based cancer registries in 13 countries, and nationwide cancer
deaths from the World Health Organization (WHO) mortality
database for 18 countries. To facilitate data comparisons across
countries, we used standard methods to check incidence data
consistency and quality [23]. All incidence data were converted to
the latest version of ICD-O (ICD-O-3) [24] and subsequently
converted to the 10th edition of the International Classiﬁcation of
Diseases (ICD-10) [25]. Nationwide mortality data from the WHO
systematically undergo data veriﬁcation, and the data are coded in
ICD-10 to avoid misclassiﬁcation of cancer mortality over time
[26]. We estimated age-standardized incidence rates (ASRs) and
age-standardized mortality rates (ASMRs) per 100,000 person-
years using the direct method and the World standard population
[27,28]. We estimated national ASRs by aggregating the data fromTable 1
Countries included in the analysis of time trends.
Country Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry the available cancer registries using a weighted average of local
rates. Trends in incidence were estimated for only four countries
that provided written consent for the use of their data or submitted
new data for about 10 years or more, and we matched mortality
data to the same time-period (Table 1). To describe incidence and
mortality time trends, we calculated the estimated annual
percentage change (EAPC) for the most recent 10-year period
using the method proposed by Esteve et al. [29]. To illustrate the
direction of the trends in incidence and mortality rates by cancer
site, locally weighted regression (LOWESS) curves were ﬁtted to
provide smoothed lines through the scatter plot of the annual age-
standardized rates by calendar period. For this report, smooth lines
were computed using a bandwidth of 0.5, which means that 50% of
the annual time-series data was used to determine the LOWESS
plotting position for each year. All of the EAPCs were tested for
equality to zero by using the corresponding standard errors. We
considered EAPCs statistically signiﬁcant if the P-value  0.05. We
conducted the data analysis in Stata version 12.1 (StataCorp) [30].
We present age-speciﬁc incidence and mortality patterns by
country and sex. For comparative purposes, we selected the same
age groups used by Hjalgrim et al. [31], except for the youngest age
groups (0–14 years) where we divide the category into two
(0–4 and 5–14 years) because the population in the region is
relatively young [32].
We also present the distribution of HL by histological subtype,
classiﬁed according to the revised WHO classiﬁcation system [24]
and used in Cancer Incidence in Five Continents [33].
3. Results
3.1. Age-standardized incidence and mortality rates
HL incidence rates varied 7-fold in males and 11-fold in females
across Central and South America. Males generally had higher HL
incidence rates than females: male-to-female (M:F) ratios ranging
from 1.1 to 4.3:1.0, except in Chile (M:F ratio 1.0:1.0) (Table 2). In
the most recent 5-year period, the highest incidence rates in males
were observed in Argentina, Cuba, Brazil and Costa Rica (ASRs of
about 2.0), whereas the lowest ASRs were in Peru, Bolivia and EL
Salvador (range 0.4–0.9). Among females, the highest incidence
rates were in Uruguay, Argentina and Brazil (ASRs 1.5) and the
lowest in Peru, French Guyana, Ecuador, El Salvador, and Bolivia
(0.14–0.67).
Mortality rates varied 4-fold in males and 6-fold in females.
Males had higher mortality than females (M:F ratios ranging from
1.1 to 2.5:1.0). Cuban males had the highest mortality rates of HL
(ASMR: 1.0) followed by Costa Rica, Mexico and Venezuela (range
0.60–0.67), while the lowest were in Brazil (0.29). Females in Cuba,
Costa Rica and Suriname had the highest mortality rates of HL
(0.54–0.63), while Panama, Brazil, Nicaragua, Paraguay (0.13–0.20)
had the lowest mortality (Table 2).
3.2. Age-speciﬁc rates
Age-speciﬁc incidence rates of HL seem to follow a bimodal
pattern among males and females in most countries in the region,
with the ﬁrst peak seen around ages 15–24 years and the secondPeriod % of the population covered
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
Table 2
Age-standardized incidence and mortality rates (per 100,000) of Hodgkin lymphoma in Central and South America by sex (all ages).
Incidence Mortality
Country (period) Sex Cases Crude rate ASR (W) M:F MV% Ranka Deaths Crude Rate ASR (W) M:F Ranka
Central America
Belize (2003–07) M 2 0.29 0.34 1.2 16
F 1 0.14 0.29 18
Costa Rica (2003–07) M 205 1.9 1.9 1.3 100 19 65 0.59 0.67 1.2 18
F 156 1.5 1.4 100 20 63 0.59 0.57 18
Cubab (2004–07) M 41 2.5 2.1 1.4 98 16 300 1.32 1.03 1.4 16
F 30 1.9 1.4 100 20 220 0.98 0.73 20
El Salvador (1999–03) M 49 0.37 0.40 1.3 88 14 59 0.41 0.49 1.2 16
F 43 0.30 0.31 88 15 56 0.36 0.41 18
Guatemala (2003–07) M 75 0.24 0.35 1.7 17
F 50 0.15 0.21 18
Mexicob (2006–10) M 231 1.3 1.4 1.3 100 15 1338 0.48 0.66 1.6 19
F 192 1.1 1.0 100 19 936 0.31 0.40 21
Nicaragua (2003–07) M 43 0.32 0.45 2.4 15
F 22 0.16 0.19 20
Panama (2003–07) M 24 0.29 0.32 1.6 19
F 15 0.19 0.20 20
South America
Argentinab (2003–07) M 265 2.2 2.1 1.4 92 19 428 0.45 0.41 1.5 19
F 212 1.6 1.5 93 22 366 0.37 0.28 22
Boliviab (2011) M 8 0.61 0.60 4.3 100 17
F 2 0.15 0.14 100 25
Brazilb (2003–07) M 1137 2.0 2.0 1.4 93 21 1268 0.28 0.29 1.5 17
F 998 1.6 1.5 95 22 912 0.19 0.19 21
Chileb (2003–07) M 28 1.2 1.1 1.0 100 22 126 0.31 0.31 1.3 20
F 27 1.2 1.1 100 22 120 0.29 0.24 21
Colombiab (2003–07) M 149 1.6 1.7 1.5 100 21 467 0.44 0.55 1.5 18
F 115 1.1 1.1 100 23 368 0.34 0.37 22
Ecuadorb (2003–07) M 55 1.2 1.3 2.4 100 20 107 0.32 0.38 1.8 18
F 29 0.56 0.52 100 23 69 0.21 0.22 20
French Guyanab(2003–08) M 8 1.6 1.8 3.1 88 20
F 3 0.60 0.58 100 23
Paraguay (2003–07) M 43 0.29 0.33 2.5 18
F 17 0.12 0.13 21
Perub (2001–05) M 85 0.92 0.95 1.4 95 23 174 0.26 0.33 1.5 18
F 68 0.71 0.67 94 22 124 0.18 0.22 20
Suriname (2003–07) M 6 0.48 0.57 1.1 15
F 6 0.48 0.54 13
Uruguay (2005–07) M 89 1.9 1.8 1.1 100 20 28 0.58 0.48 2.2 19
F 91 1.8 1.6 100 21 17 0.33 0.22 22
Venezuela (2003–07) M 342 0.51 0.61 1.4 16
F 257 0.39 0.42 20
ASR (W), age-standardized (world population) rate per 100,000; M, males; F, females; M:F, male-to-female ratio (female is the referent category). Numbers in italics, rates
estimated with <10 cases which should be interpreted carefully.
a Rank based on highest ASR excluding: All sites but C44 and All sites.
b Incidence rates were estimated using data from regional cancer registries.
S160 G. Kusminsky et al. / Cancer Epidemiology 44S (2016) S158–S167peak around ages 60 years. Age-speciﬁc incidence rates for males
in Ecuador and Peru showed a slightly different pattern, with the
ﬁrst peak occurring at 5–14 years and the second peak at ages
50–59 years. Incidence rates in boys 5–14 years in Ecuador and
Peru were 1.2 and 1.9 times higher than in young men
(20–24 years), respectively. HL incidence rates displayed more
than two peaks in males in Costa Rica and females in Chile,
Colombia, Ecuador, and Peru: one at ages 15–19, the second in
young adults (20–29), and the third in older adults (50 years).
Females in Uruguay also showed more than two peaks: one at ages
15–19, the second at ages 30–49, and the third in older adults
(60 years) (Fig. 1). HL mortality rates steadily increased with age,
reaching a maximum in older males and females, around age
65 years (Fig. 2).
3.3. Time trends
Age-standardized incidence rates in the four countries evalu-
ated did not reveal a clear pattern, with the exception of Costa Rica
where incidence seemed stable. In contrast, age-standardizedmortality rates tended to decline (Fig. 3). Trends analysis showed
no statistically signiﬁcant changes in age-standardized incidence
and mortality rates from HL for the most recent 10-year period
(1997–2008) (Fig. 4).
3.4. Histological distribution of HL incident cases in Central and South
America
About half (48%) of the HL cases diagnosed in the region in both
males and females were unspeciﬁed, while 49% were classiﬁed as
classic HL (cHL) and 3% as nodular lymphocytic HL. Among the cHL,
the most frequent tumors were nodular sclerosis (NS) and mixed
cellularity (MC), accounting for 31% and 13% of all HL diagnoses
respectively. In contrast, the least frequent cHL diagnosed were
classic lymphocyte-rich and lymphocyte-depletion types, account-
ing for 3% and 2% of all HL tumors, respectively (Table 3).
The (median) age at diagnosis was 27 years (range 0–87) for
nodular lymphocytic, 47 years (range 4–88) for classic lympho-
cyte-rich, 28 (range 1–90) for NS, 40 years (range 2–90) for MC,
Fig. 1. Age-speciﬁc incidence rates (per 100,000) of Hodgkin lymphoma in males (solid blue line) and females (dashed red line).
G. Kusminsky et al. / Cancer Epidemiology 44S (2016) S158–S167 S16147 years (range 2–87) for lymphocyte depletion, and 36 (range
2–100) for unspeciﬁed HL (Table 3).
4. Discussion
4.1. Patterns of HL incidence and mortality
This study showed a considerable variation in incidence (7-fold
in males and 11-fold in females) and mortality (4-fold in males and
6-fold in females) of HL across the Central and South American
region. In most countries, males had higher incidence and
mortality rates than females (except in Chile and Uruguay). These
geographical disparities may reﬂect differences in data quality and
coverage within the region. Geographic differences in HL rates and
sex disparity in HL rates have been documented around the world
[34,35].
Cuba had one of the highest HL mortality rates in the world in
both males and females (1.0 and 0.7, respectively), surpassed only
by Greece (1.3 and 0.7) during 2003–2007. However, the mortality
rates from Brazil, Belize, Chile, Ecuador, Guatemala, Peru, Paraguay,Panama, and Uruguay were comparable to the mortality rates
reported in more developed areas of the world [26]. Such contrasts
may reﬂect differences or inadequacies in the adoption of modern
therapies across Central and South American countries, particu-
larly among younger populations [6,19,36–39]. It is also possible
that delays in HL diagnosis and disease stage [36,40–42] could have
inﬂuenced the mortality patterns seen in the region. In Cuba, for
example, a study conducted in Santa Clara revealed that 88%
(84/96) of the HL adult patients were diagnosed at advanced
stages, and 25% of them died (23/96) from this disease [40].
We observed a bimodal pattern in age-speciﬁc incidence rates
of HL in most Central and South American countries, which is
consistent with the patterns described for European, American,
and Australian populations [9–11,14,43]. A similar pattern has been
reported among Hispanics in the United States: one peak at ages
20–29 years followed by an exponential increase until another
peak in the elderly (70–79 years) [9]. This pattern is known as the
“third pattern” which is described in developed countries and
patients with high socioeconomic status (SES). It is characterized
by a low incidence in children, high incidence in young adults and a
Fig. 2. Age-speciﬁc mortality rates (per 100,000) of Hodgkin lymphoma in males (solid blue lines) and females (dashed red lines).
S162 G. Kusminsky et al. / Cancer Epidemiology 44S (2016) S158–S167second high incidence peak in older age groups, with tumors
mainly of NS subtype and Epstein–Barr virus- (EBV-)negative
tumors [13,14,43,44].Interestingly, we observed higher incidence rates in boys
(5–14 years) as compared to young men (20–24 years) in Ecuador
and Peru, a ﬁnding more consistent with the “second pattern”
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G. Kusminsky et al. / Cancer Epidemiology 44S (2016) S158–S167 S163which is observed in countries with transitional economies and
rural areas. In this pattern, the incidence of HL has peaks in
childhood and then peaks again during the second decade of life.MC and NS subtypes are present in similar proportions in both age
groups [13,14,43,44].
The bimodal age-speciﬁc incidence pattern was less evident in
males in Costa Rica and females in Chile, Colombia, Ecuador, Peru,
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did not identify the “ﬁrst pattern”, usually seen in developing
countries and patients of low SES, where the incidence of HL is
characterized by a peak in early childhood, low incidence in the third
decade and high incidence among the oldest age groups. These
tumors are usuallyof the MC subtype, and a high proportion are EBV-
positive [13,14,43,44]. This observation seems consistent with the
hypothesis that the age-speciﬁc pattern in the region is becoming
more like the pattern seen in economically developed countries [14].
Mortality rates did not display the same age-speciﬁc incidence
pattern; instead mortality rates steadily increased with age, which is
also consistent with other reports [6,19].
Trends in HL incidence and mortality in Argentina, Brazil and
Chile did not reveal a clear pattern, whereas in Costa Rica rates
seemed stable. The interpretation of incidence trends is challeng-
ing because of the evolving classiﬁcation system, and improve-
ments in disease detection and cancer registration over the past
20 years [46]. Moreover, given the rarity of this cancer, the
observed ﬂuctuations may reﬂect instability of rates due to low
numbers. Mortality rates tended to decline or remained almost
unchanged from 1997 to 2008 in the four countries analyzed. Small
declines in HL mortality rates have also been described for males in
Cuba and Mexico and females in Ecuador and Mexico, whereas in
Colombian females HL mortality has increased from 1997 to 2008
[6]. The declines in HL mortality are probably due to therapeutic
advancements; however, changes in diagnosis and classiﬁcation
may also have played a role [6].
We were unable to examine incidence rates by histological
subtype in detail given that 48% of all the HL cases diagnosed in the
region were unspeciﬁed. NS and MC subtypes accounted for 31%
and 13%, respectively, of all HL cases diagnosed in the region. The
high frequency of NS and MC, as compared to other subtypes, seem
consistent with the histological subtypes found more frequently in
populations of higher SES and with the second and third age-
speciﬁc patterns described above [14,31]. In spite of the wide
variation in age at diagnosis of HL subtypes, the (median) age of
diagnosis of most subtypes observed in the region seem consistent
with that in other reports [12,34]. For instance, NS patients are
usually adolescents and young adults, while MC patients are
usually children or older adults. Lymphocyte-rich HL usually
occurs at ages 50 years. We observed that lymphocyte-depleted
cases were diagnosed at (median) age 47 years (range 2–87), but
this subtype usually occurs among elderly patients and in
developing countries [12]; this discrepancy could be a reﬂection
of the large proportion of unspeciﬁed cases.
4.2. Factors associated with HL risk
Explaining the geographical differences and age-speciﬁc
patterns in HL rates is challenging given that the etiology of this
disease remains largely unknown. Infections with EBV and human
immune deﬁciency virus type 1 (HIV-1) are the only established
agents with sufﬁcient evidence to be classiﬁed as carcinogens in HL
in humans [47]; differences in their prevalence could therefore, at
least in part, explain some of the observed variations across Central
and South America.
EBV has been associated mainly with cHL, and EBV-positive
tumors tend to occur more frequently in children and the elderly
[15,34]. Several studies conducted in the region have shown a wide
variation in the prevalence of EBV positivity among patients with
cHL: 45% in Argentina, 46–94% in Brazil, 69% in Colombia, 44% in
Costa Rica, 100% in Honduras, 61–92% in Mexico, and 94% in Peru
[48–50]. In Central and South America and the Caribbean, the
prevalence of EBV positivity among men with cHL was 35% higher
than in women with cHL (95% conﬁdence interval, 0.89, 2.04) [48].
In 2008, 49% of the total number of HL incident cases estimated to
G. Kusminsky et al. / Cancer Epidemiology 44S (2016) S158–S167 S165occur globally were attributed to EBV (33,000/68,000), 70%
(23,000) of which were in less developed regions of the world
[51]. In 2010, 44.7% of the total number of HL deaths estimated to
occur worldwide were attributable to EBV (7917/17,718 cases) [52].
HIV-1 has been strongly associated with an increased risk of
many cancers, including HL, mainly via immunodeﬁciency [47,53–
55]. MC and lymphocyte-depleted subtypes are prevalent in
patients with HIV infection and in developing countries [56]. In
most Central and South American countries, the prevalence of HIV
among 15–49-year-olds (0.6% in 2013) is lower than the global
prevalence of HIV in 15–49-year-olds (0.8%) or in Africa (5.5%). In
Belize and Guyana, however, the prevalence of HIV is higher than in
most countries in the region (1.5% and 1.4%, respectively) [57]. This
suggests that HIV infection probably plays a minor role in the
observed geographic differences in HL rates in the region.
Twin and familial aggregation and population-based registry
studies suggest that family history of HL may play a role in HL
development [2,58–60]. Genome-wide association studies (GWAS)
have identiﬁed 15 SNPs from nine different loci associated with HL,
with the strongest associations reported for SNPs mapping to the
human leukocyte antigen (HLA) class II [60]. HLA regions are
associated with the development of several cancers and immunity
disorders [61]. GWAS have also identiﬁed three single-nucleotide
polymorphisms (SNPs) on chromosome 6p21.32 strongly associ-
ated with an increased risk of NS among adolescents and young
adults of European origin [62].
Racial/ethnic disparities in HL rates have been reported in the
United States [9]. Epidemiological studies have shown that some
variability in HL rates across ethnic groups remains even after SES
and environment-related factors are taken into account, suggest-
ing possible differences in genetic susceptibility [9,63,64]. We
were unable to evaluate whether such associations exist within the
region because cancer registries do not systematically record this
variable. In fact, we observed elevated incidence rates in regions
with a large percentage of mostly White or European descendants
or Mestizos (Argentina and Costa Rica) as well as in regions with a
large percentage of Black populations (i.e. Brazil and Cuba) [65].
The study of race/ethnicity and HL risk in the region is very
challenging given the racial heterogeneity of the population
[66,67]. Racial categories are based on the subject's perception of
skin color which are inﬂuenced by socioeconomic position [66];
this could in turn reﬂect differences in healthcare access and
management of the disease.
Some studies among immigrant populations from Eastern Asia
and China to North America revealed that the incidence of HL has
increased in recent decades, probably due to the adoption of
Western lifestyles and environmental exposures [2,9,31]. Epide-
miological evidence is linking tobacco smoking with an increased
risk of HL, although not consistently [68,69]. Speciﬁcally, smoking
is associated with risk of EBV-positive HL but not with EBV-
negative HL [68]. However, it remains unknown to what extent
these factors could explain the observed variation in HL rates in
Central and South America.
4.3. Strengths and weaknesses of the study
This study presents a comprehensive analysis of HL incidence
and mortality rates in Central and South America. However,
incidence data patterns must be interpreted with caution given
that national data coverage was suboptimal, with the exception of
that in Costa Rica and Uruguay. Cancer registries in Central and
South America may differ in completeness and data quality which
depend on the maturity of the cancer registry, and this could
explain why some of the rates observed in Mexico, Bolivia and El
Salvador were low. The estimation of HL mortality rates may be
inﬂuenced by the quality of national registration of causes of death.In some Central and South American countries, mortality data may
be considered of medium or low quality [70]. Moreover, incidence
rates from Bolivia and French Guyana and mortality rates from
Belize and Suriname must be interpreted with caution as they were
estimated using less than ten cases and may not be stable.
Because we chose to present incidence rates by country rather
than by cancer registry, our results do not depict possible within-
country differences related to the catchment area of the
population-based cancer registries. However, due to the rarity of
HL, several cancer registries recorded less than ten cases by sex.
The estimation of rates based on such low numbers of cases would
have led to unstable age-standardized incidence rates and unclear
age-speciﬁc patterns [71].
Regarding data quality indicators, the percentage of micro-
scopically veriﬁed (MV) cases (validity of the diagnostic informa-
tion) in most Central and South American countries was high
(ranging from 98% to 100%) and comparable to the MV% observed
across good-quality cancer registries in other parts of the world
(i.e. North America, Africa, United Kingdom), where MV% ranged
from 98% to 100% [71]. In Argentina, Brazil, El Salvador, French
Guyana, and Peru, the MV% was lower than that in the rest of the
countries in the region (ranging from 88% to 94%) (as shown in
Table 2). Despite this, the MV% in our study is higher than that
reported previously for Argentina, Brazil and Chile [6]. In contrast,
all cancer registries across the region had poor diagnostic
precision, as 48% of all HL incident cases were classiﬁed as
unspeciﬁed by histological classiﬁcation [72]. It is uncertain
whether the observed geographic variation in HL rates is
artefactual or not; however, our results highlight the need for
high-quality data and increased coverage in order to provide vital
guidance for future cancer control activities.
5. Conclusion
HL is a relatively rare cause of cancer incidence and mortality in
the Central and South American region. Nevertheless, rates
showed important geographic variations, perhaps reﬂecting
differences in data quality and coverage within the region as well
as differences or inadequacies in the adoption of modern therapies
and healthcare access. This study revealed marked differences in
age-speciﬁc rates. The most frequent age-speciﬁc pattern was
consistent with the pattern observed in countries with transitional
economies and rural areas. This study also revealed concerns
regarding data quality of HL by histological classiﬁcation, as 48% of
the cases were unspeciﬁed; this underlines the need to improve
the quality of registrations in the region.
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